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One of the more perplexing aspects of urinary tract infections (UTIs) is their high propensity to recur. It has
been proposed that recurrent infections are a result of the reintroduction of bacteria from the gastrointestinal
tract (GIT) to the urinary tract (UT); however, since a significant subset of recurrent UTIs are caused by an
identical bacterial strain, it has been challenging to formally prove this hypothesis for same-strain recurrences
by using epidemiologic approaches. We present data here obtained by using a mouse model of UTIs in which
it was shown that 36% (5 of 14) of mice infected with uropathogenic Escherichia coli (UPEC) will have at least
one bacteriuric recurrence, with 21% (3 of 14) having more than one recurrence during a 6-week period after
an acute UTI. Intraurethrally infected mice develop UPEC reservoirs in both their feces and their bladders.
Ten days of trimethoprim-sulfamethoxazole (SXT) therapy reduces urinary recurrences and eradicates fecal
colonization, whereas 3 days of SXT treatment has no effect over a twenty-eight-day observation period despite
clearing fecal colonization acutely. Interestingly, SXT is unable to eradicate bacteria from the bladder reservoir
even after a 10-day treatment regimen, thus demonstrating that the bladder reservoir can persist even in the
face of long-term antibiotic therapy.
Recurrent urinary tract infections (UTIs) are a common
clinical problem. Up to 25% of women who present with an
acute UTI will have a recurrence within 6 months, despite
receiving appropriate antibiotic therapy (3). The majority of
both acute and recurrent UTIs are caused by uropathogenic
Escherichia coli (UPEC) (7). Interestingly, a significant num-
ber of recurrent UTIs are caused by the identical strain of E.
coli isolated from the index UTI (1, 4, 10, 11, 18). Recurrences
within the first month of infection are even more likely to be
caused by the same strain of E. coli (10, 18). In some instances,
infections caused by the same bacterial strain have been ob-
served over a year after the original infection (23).
The high frequency of the same strain recurrences suggests
the existence of a UPEC reservoir in close proximity to the
affected individual. The current dogma is that recurrent UTIs
result from the reinoculation of the UT with bacteria originat-
ing from the gastrointestinal tract (GIT) flora (6). Consistent
with this idea, it has been demonstrated that the GIT and the
vaginal-periurethral areas can be a reservoir for UPEC (18,
22). In addition, vaginal epithelial cells from women that are
prone to recurrent UTIs tend to support higher levels of bac-
terial adherence compared to cells from healthy controls (20).
However, the presence of perineal bacterial colonization, or
GIT colonization, does not predict the risk of recurrence in
girls or women with anatomically normal urinary tracts (UTs),
arguing that there are additional factors involved in recurrent
UTI pathogenesis (21, 25). Previous studies have also shown
that the daily application of antibacterial ointment to the per-
ineal area fails to prevent recurrent infections, even though
such a treatment would be expected to block fecal to UT
transmission (2). Such results suggest that the GIT and peri-
neal areas may not be the only reservoir for UPEC.
The observation that bacteria are cleared from the urine
following an acute UTI has led to the assumption that UPEC
is eradicated from the urinary tract. However, this view has
been challenged by a recent study demonstrating that mice
infected with type 1-piliated UPEC are able to persist in the
bladder for up to 6 weeks after acute infection in the absence
of bacteriuria (8, 16). Thus, the bladder appears to be a pre-
viously unrecognized long-term reservoir for UPEC, which
may contribute to the recurrent nature of UTIs. Virtually all
uropathogenic E. coli express type 1 pili, which mediate bind-
ing to and invasion into uroplakin-coated bladder epithelial
cells. The FimH-uroplakin interaction activates signal trans-
duction pathways, leading to the invasion of the bacterium into
the superficial umbrella cells, where they are protected from
the flow of urine and other host defenses (9, 19). UPEC rep-
licates rapidly once inside these cells, creating large foci of
bacteria called “bug factories.” The host responds by initiating
numerous innate defenses in the bladder. An apoptosis-like
response is activated, leading to the exfoliation of the superfi-
cial umbrella cells under attack by the invading pathogen.
Complex signaling pathways are also activated and result in the
host inflammatory response. In order to persist in the bladder
in the face of these host defenses, the UPEC bug factories
“flux” or break out of umbrella cells and colonize the exposed
underlying transitional epithelium as part of a process to in-
vade deeper tissues and establish a chronic reservoir, which in
mice can persist for months in a quiescent state (17).
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The majority of acute UTIs respond well to antibiotic ther-
apy with agents such as trimethoprim-sulfamethoxazole (SXT).
The recommended treatment regimen for women with acute
cystitis is a 3-day course of antibiotics; however, despite cure of
the acute infections, as defined by clearance of bacteria from
the urine, the rate of relapse or recurrence is as high as 15%
within 6 weeks after the cessation of treatment (14). In addi-
tion, prophylactic antibiotic therapy is commonly used for the
management of recurrent UTIs; however, if the antibiotics are
discontinued, the infections tend to recur (24). In the present
study, we sought to investigate the potential role of the bladder
bacterial reservoir in recurrent bacteriuria and to determine
how the duration of antibiotic therapy affects the natural his-
tory of bacterial persistence and recurrence.
MATERIALS AND METHODS
Bacteria and growth conditions. UTI89 (16) and UTI89 SR (a streptomycin-
resistant derivative of the same strain) were grown static for 48 h in Luria broth
at 37°C to induce the expression of type 1 pili. UTI89 is SXT sensitive.
Mouse inoculations. C57BL/6 female mice were obtained from Jackson Lab-
oratory. A 48-h culture of UTI89 was pelleted and resuspended in sterile phos-
phate-buffered saline (PBS) at a concentration of ca. 2  109 CFU/ml. Eight- to
twelve-week-old mice were infected via intraurethral inoculation with 50 l of
the bacterial suspension (108 CFU) (15). Anal lavages were performed by using
100 l of the same bacterial suspension described above. At the indicated times
after infection, mice were individually induced to urinate by applying gentle
pressure to the skin just below the occiput. The clean-catch urine samples were
collected into sterile Eppendorf tubes, and the bacterial titers were determined
by plating serial dilutions of the material onto Luria-Bertani (LB) agar with or
without streptomycin. Fecal samples were likewise collected individually and
subsequently homogenized in 250 l of LB medium. The homogenate was plated
onto streptomycin-containing agar plates to determine the fecal titer. Care was
taken to ensure that cross-contamination between urine and fecal samples did
not occur. Bacterial titers in the bladder or kidney were determined by homog-
enizing the tissue in 500 l or 1 ml of sterile PBS containing 0.025% Triton
X-100, respectively, and plating out serial dilutions of the homogenate onto LB
agar with or without streptomycin.
For the antibiotic therapy experiments, mice were treated for the indicated
duration with SXT (Qualitest Pharmaceuticals, Huntsville, Ala.) at concentra-
tions of 54 and 270 g/ml, respectively, in their drinking water.
DNA fingerprinting. The techniques and primer sets for the arbitrarily primed
PCR fingerprinting were used as previously described (12).
RESULTS
Recurrent bacteriuria in mice infected with UPEC. It has
previously been observed that mice with reservoir levels of
bacteria in the bladder (50 to 1,000 CFU/bladder) have sterile
urine, whereas mice with acute infection levels of bacteria in
the bladder (105 to 107 CFU/bladder) have high-titer bacteri-
uria (16). These results suggested that it would be possible to
study recurrences of the same strain bacteriuria by using a
kinetic analysis of urine bacterial titers. In an initial experi-
ment, five mice from one cage (cage 1) were infected with
UTI89, a clinical cystitis strain, via intraurethral inoculation,
and urine samples were collected every other day for 6 weeks.
Two of the five mice (M1 and M4) had at least one recurrent
episode of bacteriuria after urine sterility had been docu-
mented (Fig. 1 and Table 1). M2 and M3 had persistent infec-
tions with high-titer bacteriuria lasting for 9 and 35 days, re-
spectively. After clearance of the initial bacterial challenge, M5
had no detectable bacteria in the urine throughout the dura-
tion of the experiment. All of the culture-positive urine sam-
ples contained between 9  103 and 3  106 CFU/ml, arguing
against the possibility of sample contamination by urethral or
vaginal organisms. At the end of 6 weeks, the mice were sac-
rificed, and bacterial titers in the bladders were determined.
Interestingly, M1, M4, and M5 all had bacteria persisting in
their bladder tissue; however, the bladders of M2 and M3 were
sterile (Fig. 2). Moreover, the left kidney of M2 was shrunken
and scarred. The kidneys from all of the mice were sterile (data
not shown).
To conclusively determine that these recurrences were
caused by the inoculated strain and to assess whether a fecal
reservoir of UPEC was established in this model of acute UTI,
nine mice (cage 2, M6 to M9; cage 3, M11 to M15) were
infected with a streptomycin-resistant strain of UTI89 (UTI89
SR). One mouse, M10, was left uninfected but remained in
cage 2 throughout the experiment. Importantly, no streptomy-
cin-resistant bacteria could be isolated from the bladder, feces,
or urine of uninfected mice or from mice infected with a
streptomycin-sensitive UPEC strain (unpublished observa-
tions). Urine and fecal samples were collected every other day
for 6 weeks, and the results are shown in Fig. 1 and Table 1.
Three of the nine infected mice had recurrent episodes of
bacteriuria after documented urine sterility with M13 having
one episode, M12 having two episodes, and M7 having four
episodes. As before, one of the mice, M8, had a persistent
infection that did not clear until day 9 after infection. The
remainder of the mice did not have any documented recur-
rences. To further demonstrate that the streptomycin-resistant
E. coli were the same as the inoculated strain, arbitrarily
primed PCR DNA fingerprinting was performed on random
isolates from bladder tissue, urine fluxes, and fecal samples
(12). All of the isolates showed the same banding pattern as
the inoculated strain (data not shown).
The analysis of fecal samples demonstrated that all of the
mice became transiently or continuously colonized with the
infecting strain of UPEC, including the uninfected mouse, M10
(Fig. 1). Recurrent bacteriuria was associated with elevations
of fecal titers in mice sharing the same cage. At the end of 6
weeks, the mice were sacrificed and bladder bacterial titers
were determined as before. All of the mice infected with
UTI89 SR (mice 6 to 15) were still colonized, except for M10
and M12, who had sterile bladders (Fig. 2). The right kidney of
M12 was distorted and showed evidence of abscesses and scar-
ring, and M10 was an uninfected control. None of the kidneys
from these mice were infected at the 6-week time point (data
not shown).
Transmission of UPEC from the UT to the GIT. The fact
that infected mice became colonized both in their bladders and
GITs makes it difficult to determine the source of bacteria
causing the recurrent episodes of bacteriuria. However, to
address the efficiency of GIT-to-UT transmission, as well as the
mouse-to-mouse spread of UPEC, one mouse of five in a cage
was infected intraurethrally with UTI89 SR. Fecal samples
collected before the infection demonstrated that SR E. coli was
not present in the feces of any of the mice (Table 2). The day
after infection, fecal samples were again taken from all of the
mice, and the fecal titers were determined. Six of the seven
uninfected mice had streptomycin-resistant E. coli in their fe-
ces 24 h after UTI89 SR was introduced to their environment
(Table 2). At 7 days after infection, fecal titers were again
determined and demonstrated that only the mice that were
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infected intraurethrally, M16 and M21, maintained fecal colo-
nization. At 14 days after infection, M16 to M20 were sacri-
ficed and their bladders, urines, and feces were cultured for
UTI89 SR. All of the urines were sterile, and only the infected
mouse had bacteria in the bladder tissue or in the feces (data
not shown and Table 2).
Since transient fecal colonization may not be sufficient to
facilitate GIT-to-UT transfer of UPEC, M22 to M25 were
given an anal lavage with UTI89 SR in an attempt to establish
fecal persistence of the uropathogen. At days 14, 21, and 25
after inoculation four of four lavaged mice still had UTI89 SR
still in their feces (Table 3). Since 90% of the recurrent epi-
sodes of bacteriuria occurred by day 25 after infection, these
mice were sacrificed at day 25, and the titers of feces, urine,
and bladder samples were determined for UTI89 SR. Impor-
tantly, it has been demonstrated that instillation of as few as
105 CFU/ml of UTI89 into the bladders of C57BL/6 mice
establishes bladder colonization for at least 1 month after the
FIG. 1. Kinetic analysis of urine and feces after infection with UPEC. C57BL/6 mice were infected with UTI89 (M1 to M5) or UTI89 SR (M6
to M15), and bacterial titers in urine () and feces () samples were determined every other day for 6 weeks (42 days). Five mice were together
in each cage with M1 to M5 (cage 1), M6 to M10 (cage 2), and M11 to M15 (cage 3). M10 was not infected with UTI89 SR. ❋, No urine collected;
, no feces collected.
FIG. 2. Bacterial persistence in the bladders of mice infected with
UPEC. Bladders were removed from the indicated mice 6 weeks after
intraurethral infection with UTI89 (M1 to M5) or UTI89 SR (M6 to
M15), and the bacterial titers in the tissue were determined. K, Kidney
scarring; B, persistent bacteriuria; U, uninfected.
TABLE 1. Recurrent and persistent bacteriuria in mice after
infection with UPEC




M4 ............................................................................. 7, 16
M7 ............................................................................. 11, 15, 25–26, 30
M8 ............................................................................. 1.5–9
M12 ........................................................................... 13, 26
M13 ........................................................................... 13
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acute infection (data not shown); therefore, if any of the mice
with persistent fecal colonization developed an acute UTI dur-
ing the experiment (where bacterial titers often exceed 107
CFU/ml), bacteria would be expected to remain in the bladder.
In this way, it is possible to assess the efficiency of GIT-to-UT
transmission in this experimental system. At day 25, only the
mouse that had undergone intraurethral infection had UTI89
SR in the bladder (Table 3). All of the urine samples were
sterile at this time point (data not shown).
To exclude the possibility that an initial bladder infection
renders the UT more amenable to colonization with GIT bac-
teria, C57BL/6 mice were initially infected with UTI89; at 2
weeks after infection the mice were subsequently given an
anal-lavage, periurethral-vaginal, or intraurethral inoculation
with NU14, a streptomycin-resistant cystitis isolate. Mice that
were previously infected with UTI89 were significantly more
resistant to colonization with NU14 instilled intraurethrally
compared to mock-infected animals [median values, 5.4  102
CFU/bladder (UTI89 preinfected) versus 1.5  105 CFU/blad-
der (mock infected), P  0.05]. The mice that were given anal
lavage or periurethral colonization did not have any strepto-
mycin-resistant bacteria in their bladders at day 28 after instil-
lation of NU14. However, all of the mice were still colonized
with UTI89 (data not shown).
The effect of 3- versus 10-day SXT therapy on UPEC per-
sistence and recurrence. To determine the effects of antibiotic
therapy on urine recurrences, as well as persistence of UPEC
in the bladder and feces, C57BL/6 mice were infected with
UTI89 SR and were subsequently left untreated or treated
with SXT in their drinking water for 3 days or 10 days. Urine
and fecal samples were collected twice on the first day after
infection and on each subsequent day for 28 days. Regardless
of the antibiotic therapy, C57BL/6 mice rapidly cleared UTI89
SR from the urine, as had been observed previously (16) (Fig.
3). The five mice that received no antibiotics had three urinary
recurrences of 103 CFU/ml in three different mice on days 4
(M27), 9 (M26), and 13 (M30) after infection. Fecal titers were
present in the majority of mice in this group throughout the
observation period. After the last urinary recurrence, on day 13
postinfection, the fecal titers progressively decreased.
In the five mice that received 3 days of SXT, fecal titers were
reduced to 10 CFU/feces in all of the mice (mean, 2.5 CFU/
feces) by the end of 3 days of antibiotic therapy. On day 4 after
infection, within 1 day after the cessation of antibiotic treat-
ment, M33 had a urinary recurrence of UTI89 SR, and on days
5 to 7 M31 also had a recurrent episode of bacteriuria, both of
which were 104 CFU/ml of urine (Fig. 3). The episodes of
bacteriuria in these mice were associated with an increase in
fecal titers for all of the mice within their cage. During the rest
of the experiment there were five additional bacteriuric recur-
rences that were 103 CFU/ml; four were in M31 (days 10 to
11, 16 to 18, 22 to 23, and 26 to 28) and one was in M33 (day
24).
The mice that were treated with SXT for 10 days, like those
treated for 3 days, rapidly cleared UTI89 SR from the feces.
Interestingly, M40 had two urinary recurrences of UTI89 SR
while on antibiotic therapy, on days 4 and 6 after infection, but
only one was 103 CFU/ml of urine (Fig. 3). Also on day 6,
fecal titers reappeared in three of five mice within the cage;
however, the magnitude of fecal colonization was substantially
lower than that typically associated with recurrent episodes of
bacteriuria in the absence of antibiotics and was rapidly
cleared after the bacteriuric episode subsided (Fig. 3). Even
after SXT was removed from the water at day 10, there was no
TABLE 2. Intra- and intermouse transfer of UPEC from the UT to GITa
Mouse no. Day 1 fecal titer(CFU/feces)
Day 1 fecal titer
(CFU/feces)
Day 7 fecal titer
(CFU/feces)
Day 14
Fecal titer (CFU/feces) Bladder titer (CFU/bladder)
M16* 0 2,000 482 207 310
M17 0 ND 0 0 0
M18 0 414 0 0 0
M19 0 488 0 0 0
M20 0 500 0 0 0
M21* 0 500 800
M22 0 0 0
M23 0 5 0
M24 0 27 0
M25 0 63 ND
a *, infected mice. M16 to M20 were in one cage, and M21 to M25 were in another cage. ND, not done.
TABLE 3. GIT colonization with UPEC does not lead to efficient spread to the UTa
Mouse no.
Fecal titer (CFU) at: Bladder titer (CFU)
at day 25Day 3 Day 7 Day 14 Day 21 Day 25
M21* 32 312 10 15 0 510
M22 ND 86 64 16 74 0
M23 107 1,012 110 845 64 0
M24 1,500 1,480 1,500 446 1,120 0
M25 402 197 1,100 282 8 0
a *, intraurethrally infected mouse. ND, not done.
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culturable UTI89 SR detected in either the urine or the feces
throughout the rest of the experiment.
To test the effect of SXT therapy on bacterial persistence in
the bladder, mice with different treatment regimens were sac-
rificed at day 3 after infection and at day 28 after infection and
bacterial titers in the bladders were determined. At day 3 after
infection the bladder bacterial titers were about four times
lower for the SXT-treated group than the untreated group
(median values, 420 CFU/bladder [untreated] versus 110 CFU
bladder [treated]); however, all of the treated mice were still
colonized (Fig. 4). Intriguingly, at day 28 after infection all of
the mice were still colonized with UTI89 SR in their bladders
irrespective of the duration antibiotic therapy (median values,
30 CFU/ml [untreated], 440 CFU/ml [3 day treated], and 180
CFU/ml [10 day treated]).
DISCUSSION
The high propensity for UTIs to recur poses a significant
challenge to the clinical management of these infections. The
current thought is that all recurrent UTIs result from reinoc-
ulation of the UT with bacteria from the GIT or vaginal-
periurethral flora. In support of this model is epidemiologic
evidence demonstrating that UPEC strains can be found in the
GIT and the vaginal-periurethral areas before and/or after an
acute UTI (18, 25). Furthermore, women who suffer from
recurrent UTIs tend to have a higher level of vaginal coloni-
zation with E. coli than do women who do not have recurrent
UTIs (22). However, it has been difficult to prove that recur-
rent infections are solely the result of reinfections from an
exogenous site by using epidemiologic approaches, especially
given the high frequency of same-strain recurrences (1, 4, 10,
11, 18). A recent study demonstrated that a clinical E. coli
pyelonephritis isolate could cause chronic infection in the li-
popolysaccharide-hyporesponsive C3H/HeJ mouse strain (5).
The data presented in the present study of recurrent bacteri-
uria in wild-type mice suggest that recurrent infections with the
same strain of E. coli may be a manifestation of chronic blad-
der colonization.
After intraurethral inoculation of C57BL/6 mice with
UTI89, a clinical cystitis isolate, the bacteria are rapidly
cleared from the urine. However, we observed that after the
initial clearance of bacteria from the urine, recurrent bacteri-
uria occurred in 36% (5 of 14) of the mice, and multiple
bacteriuric episodes occurred in 22% (3 of 13) of the mice. The
majority of the bacteriuric episodes had urine titers of 104
CFU of E. coli/ml. By using a streptomycin-resistant strain of
UTI89 it was determined that all of the mice, including an
uninfected mouse in the same cage as the infected mice, de-
veloped either transient or continuous fecal colonization with
this E. coli strain after intraurethral inoculation. Arbitrarily
primed PCR DNA fingerprinting was also used to further show
that the E. coli isolates from the urine and feces were identical
to the inoculated strain. Thus, in this animal model, bladder
and fecal UPEC reservoirs are established after acute infection
with UTI89. The most likely mode of UPEC transmission from
the UT to the GIT is via a urine-oral route; however, it is
possible that alternate routes exist for bacterial spread from
the UT to the GIT. The vaginal reservoir of UPEC was not
directly assessed in the present study and will be the focus of
future investigations.
The transmission of UTI89 SR from infected mice to the
GIT of uninfected mice is an efficient process, as 86% (six of
seven) of the uninfected mice produced fecal specimens that
became positive for UTI89 SR after exposure to an acutely
infected cagemate. However, 1 week later the same uninfected
mice no longer had UTI89 SR in their feces. However, the
feces of both of the infected mice remained colonized, suggest-
ing that maintenance of the fecal titer is enhanced by the
persistence of bacteria in the bladder and that UPEC in the
feces at levels of 102 CFU/feces is unable to efficiently colonize
FIG. 4. Effect of SXT on bacterial persistence in the bladder. C57BL/6 mice were infected with UTI89 SR and treated with SXT for 3 days
(black circles) or 10 days (red circles) or were left untreated (white circles). Bladders were harvested at days 3 and 28 after infection, and serial
dilutions of the bladder homogenates were titered to determine the level of culturable UTI89 SR remaining in the bladder. The black bars indicate
the median values.
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the GIT of other animals. When the mice (M16 to M20) were
sacrificed at day 14 after the introduction of the infected
mouse, only the infected mouse (M16) had UTI89 SR in the
bladder, suggesting that GIT-to-UT transmission had not oc-
curred in M17 to M20. M16 still had significant numbers of
UTI89 SR in its feces but at decreased levels compared to the
initial colonization level (Table 2).
Because of the intimate relationship between fecal coloni-
zation and bacteriuria, it is difficult to conclusively state which
event facilitates the other. Regardless, these observations sug-
gest that transmission from the UT to the GIT may be a means
by which UPEC maintains itself within a particular host and
illustrates the complex host-pathogen network established dur-
ing an acute infection with UPEC. In addition, the fact that
M10 maintained bladder sterility despite having fecal coloni-
zation with UTI89 and being in a cage with four other infected
mice for 6 weeks suggests that spread from the feces to the UT
is a rare event in this experimental system. Further support for
this conclusion comes from the anal lavage experiments,
wherein fecal colonization was established in the absence of
bladder colonization, and the UTs of these mice remained
sterile up to 25 days postlavage. In fact, these data are consis-
tent with results from epidemiologic studies in which it has
been shown that the detection of UPEC isolates in the feces
does not predict the risk of a UTI (25).
Acute UTIs are treated with antibiotics, such as SXT (7).
The majority of the time antibiotics clear bacteriuria and result
in the resolution of symptoms. However, despite appropriate
antibiotic therapy UTIs still recur. To test the impact of SXT
therapy on the bladder and fecal reservoirs after an acute UTI,
mice were treated with SXT for 3 days or 10 days or left
untreated after intraurethral inoculation with UTI89 SR. Mice
who did not receive antibiotics or received a 3-day course of
antibiotics had several urinary recurrences of103 CFU/ml. In
contrast, of the five mice that received a 10-day course of SXT
there was only one urinary recurrence of 103 CFU/ml, which
occurred during antibiotic therapy. SXT therapy was associ-
ated with a rapid decline in the fecal titers of UTI89 SR;
however, the mice that received only 3 days of therapy had a
resurgence of fecal colonization that was associated with
UTI89 SR reappearing in the urine. In contrast, the mice that
received 10 days of antibiotic therapy had only one mild and
short-lived fecal reemergence; however, it was also associated
with the episode of recurrent bacteriuria in this treatment
group. Interestingly, there were no urinary recurrences or de-
tectable fecal titers in the 10-day-SXT-treated group between
days 10 and 28 after infection, after the antibiotic had been
removed. Together, these data demonstrate that 3 days of SXT
treatment does not alter the course of urinary recurrences in
this mouse model, despite clearing UPEC from the fecal res-
ervoir and reducing bacterial titers in the bladder during the
acute phase of the infection. However, 10 days of SXT therapy
appeared to reduce urinary recurrences of UTI89 SR and
eradicated the fecal reservoir through day 28 after infection.
Importantly, all of the mice were still colonized with UTI89 SR
in the bladder at day 28 after infection irrespective of antibiotic
therapy, demonstrating that the bacterial reservoir is very sta-
ble even in the face of antibiotics. The persistence of UTI89
SR after 10 days of antibiotic therapy raises the possibility that
at some later time these bacteria could serve as a seed for a
subsequent recurrent bacteriuric episode. When interpreting
these results with respect to the recurrent UTIs in a clinical
population, it is important to remember that the environment
in a mouse cage is quite distinct from most human habitations,
necessitating future analysis testing the clinical relevance of
these results. Irrespective of this fact, these findings illustrate
that the interplay between the GIT and the UT is complex and
clearly show that the persistence of bacteria in the bladder
significantly alters the risk of recurrent bacteriuria and persis-
tence of bacteria in the GIT. These findings are particularly
interesting in light of the recent discovery that a particular
uropathogenic clone of E. coli has disseminated to several
locations within the United States (13). In addition, 10-day
SXT therapy is more effective at preventing bacteriuric recur-
rences and subsequent reseeding of the GIT than 3 days of
SXT therapy; however, neither of these regimens eradicates
UTI89 SR from the bladder reservoir. Future studies designed
at investigating the bacteriologic properties of persistent E.
coli, as well as the potential triggers for bacterial reemergence
from the bladder reservoir, could facilitate the development of
new treatment modalities for recurrent UTIs focused on the
eradication of persistent bacteria from the bladder.
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